Nivolumab + Anti-LAG-3 Antibody in Metastatic Melanoma

Nivolumab + Anti-LAG-3 Antibody in Metastatic Melanoma

User Photo
AnnualMeeting2017

3 years
776 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Shailender Bhatia, MD of Seattle Cancer Care Alliance discusses his second presentation, which focused on the use of nivolumab plus an anti-LAG 3 antibody for the treatment of metastatic melanoma at the 2017 ASCO Annual Meeting in Chicago, IL.

Abstract 9520: Initial efficacy of anti-lymphocyte activation gene-3 (antiLAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with antiPD-1/PD-L1 therapy
Up Next Autoplay
>